HOME >> BIOLOGY >> NEWS
Gene Shears In Cutting Edge Anti-Aids Trial

CSIRO's revolutionary "gene shears" technology has entered clinical trials in adults as the first step in developing a potential treatment for the human immunodeficiency virus (HIV) which causes AIDS, the chief executive of Gene Shears Pty Ltd, Dr Leigh Farrell announced today.

The Phase One clinical trial, conducted at St Vincent's Hospital, Sydney, is testing the safety and ability of Gene Shears' patented gene therapy to inhibit HIV replication in infected patients.

HIV attacks a special class of white blood cell, the CD4+ lymphocyte, which forms the backbone of the human immune defence against attacks by infection. Loss of these white blood cells causes the immune system eventually to break down.

The basis for the trial is the original discovery by CSIRO Plant Industry molecular biologists Dr Jim Haseloff and Dr Wayne Gerlach that naturally-occurring enzymes called ribozymes (dubbed "gene shears") can be used selectively to chop up pieces of genetic material. Gene Shears Pty Ltd went on to prove in laboratory experiments that ribozymesit could be used to prevent the replication of HIV by cutting its genetic material.

The chief executive of CSIRO, Dr Malcolm McIntosh, welcomed news that human trials of the anti-HIV gene shears were under way. "It is extremely pleasing that this fundamental Australian discovery is now starting to bear fruit in the form of practical applications which promise to improve human health and wellbeing," he said.

"It highlights the national importance of CSIRO continuing to perform excellent basic science designed to gain new knowledge."

The Sydney experiment involves six pairs of identical twins, of whom one of each pair is HIV-positive.

CD4+ white blood cells taken from the uninfected twin are equipped with the anti-HIV ribozyme and then infused into the HIV-infected twin.

The trial seeks first to establish that the ribozyme is safe and has no side-effects on the patien
'"/>

Contact: Dr Leigh Farrell
genes@ozemail.com.au
61-2-9878-8200
CSIRO Australia
4-Aug-1997


Page: 1 2

Related biology news :

1. Cutting-edge cancer researchers sought for international recognition
2. Cutting back on cigarettes: when less is more
3. AChemS: Cutting edge research in taste, smell, & chemical irritation
4. Cutting edge
5. Cutting-edge research to be presented at ASCPT pharmacology conference
6. Cutting the risk of coronary disease - start before birth says UK doctor
7. Story Tips: Engineering Students Pursue Cutting-Edge Research
8. Brain Building May Depend On DNA Cutting And Pasting
9. Cutting The Time And Cost Of Developing New Cures: Lord Sainsbury Launches Worlds First Biomedical Accelerator Mass Spectrometer In York
10. Flexibility In Cutting Toxic Releases Yields Dividends
11. Trial shows which brain cancer patients benefit from temozolomide

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/16/2019)... , ... June 14, 2019 , ... ... invited to lecture at the fifth annual Neodent World Congress. Attended by thousands ... innovative progress and latest advancements in the world of dentistry. The three-day event ...
(Date:6/11/2019)... , ... June 12, 2019 , ... ... antibody discovery services, Abveris plans to leverage the Geneious Biologics platform as a ... Souders, Chief Technology Officer at Abveris, says: “The Geneious team has done an ...
(Date:6/4/2019)... ... June 04, 2019 , ... In’Tech Medical SAS ( ... Q1-19 revenues of $31M, up 12% from Q1-18. The growth is associated with ... & operational excellence initiatives worldwide. , Laurent Pruvost , President & CEO ...
Breaking Biology News(10 mins):
(Date:6/11/2019)... ... June 11, 2019 , ... ... Stem Cells Inc. (PSC) , has announced that their GMP facility for cell ... Drug Branch for manufacturing. This is an important milestone for VetStem as ...
(Date:5/31/2019)... ... May 29, 2019 , ... ... applications from the USPTO providing proprietary interest to our methodology, processes, and ... DISORDER DIAGNOSIS AND TREATMENT… extends Somnology’s IP rights including our proprietary sleep ...
(Date:5/22/2019)... ... May 22, 2019 , ... Artemis (formerly Agrilyst), the ... Series A funding round co-led by Astanor Ventures and Talis Capital ... and iSelect Fund . The company has raised $11.75m to date and ...
(Date:5/14/2019)... ... May 13, 2019 , ... Leak Detection Associates ... the Pharmaceutical, Biotechnology, Medical Device and Food Packaging Industries’ is excited to announce ... to improve LDA’s ability to communicate directly with the marketplace; serving as a ...
Breaking Biology Technology:
Cached News: